Mazitschek, Ralph, PhD
Dr. Mazitschek is an Assistant Professor at Harvard Medical School and Co-Director of the Chemical Biology Platform at the Center for Systems Biology at Massachusetts General Hospital (MGH). Dr. Mazitschek is also a member of the Infectious Diseases Initiative at The Broad Institute of Harvard and MIT, associate Faculty at the Center for Human Genetic Research at MGH and Visiting Scientist at the Department of Immunology and Infectious Diseases at Harvard School of Public Health.
Dr. Mazitschek graduated from the University of Leipzig in 2002 with a Ph.D. in Organic Chemistry. He continued hist research at the Institute of Chemistry and Cell Biology (ICCB) at Harvard Medical School first as postdoc and later as Institute Fellow, from which he joined the Chemical Biology Program at the newly founded Broad Institute of Harvard and MIT. In 2008 he joined the faculty of the Center for Systems Biology at the Massachusetts General Hospital to continue his independent research.
HDAC3 regulates DNMT1 expression in multiple myeloma: Therapeutic implications.
Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging.
Nat Protoc. 2017;12(7):1472-1497 - PMID: 28686582
Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia.
Cell Chem Biol. 2017;24(7):892-906.e5 - PMID: 28712747
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Modular Bi-Directional One-Pot Strategies for the Diastereoselective Synthesis of Structurally Diverse Collections of Constrained β-Carboline-Benzoxazepines.
Lysine Deacetylation by HDAC6 Regulates the Kinase Activity of AKT in Human Neural Progenitor Cells.
ACS Chem Biol. 2017;12(8):2139-2148 - PMID: 28628306
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice.
Histol Histopathol. 2017;:11885 - PMID: 28245046